Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose-escalation Trial of OMTX705, an Anti-fibroblast Activation Protein Antibody-drug Conjugate, as Single Agent and in Combination With Anti-PD-1 in Patients With Advanced Solid Tumors

NCT05547321 is registered in ClinicalTrials.gov with Oncomatryx Biopharma S.L. as lead sponsor.

NCT NCT05547321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05547321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose-escalation Trial of OMTX705, an Anti-fibroblast Activation Protein Antibody-drug Conjugate, as Single Agent and in Combination With Anti-PD-1 in Patients With Advanced Solid Tumors
Lead sponsor
Oncomatryx Biopharma S.L.
Phase
Phase 1
Overall status
Recruiting
Start date
October 20, 2022
Completion date
December 31, 2027
Enrollment
150 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor